6) Cellule staminali mesenchimali: un nuovo strumento terapeutico per l’AKI

Nat Rev Nephrol. 2010 Mar;6(3):179-83.

Mesenchymal stem cells: a new therapeutic tool for AKI.

Tögel FE, Westenfelder C.
Department of Medicine, Weill Cornell College of Medicine and New York Presbyterian Hospital, New York, NY 10021, USA.


Acute kidney injury (AKI) is a common clinical complication, associated with poor outcomes and the development of chronic kidney disease. Despite major advances in the understanding of its pathophysiology, available therapies for AKI are only supportive; therefore, adequate functional recovery from AKI must predominantly rely on the kidney’s own reparative ability. An extensive body of preclinical data from our own and from other laboratories has shown that administration of adult multipotent marrow stromal cells (commonly referred to as mesenchymal stem cells [MSCs]), effectively ameliorates experimental AKI by exerting paracrine renoprotective effects and by stimulating tissue repair. Based on these findings, a clinical trial has been conducted to investigate the safety and efficacy of MSCs administered to open-heart surgery patients who are at high risk of postoperative AKI. In this Perspectives article, we discuss some of the early data from this trial and describe potential applications for stem cell therapies in other fields of nephrology.